{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:27:07Z","timestamp":1773916027475,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Merck, Whitehouse Station, NJ"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.ijcard.2011.12.103","type":"journal-article","created":{"date-parts":[[2012,2,4]],"date-time":"2012-02-04T03:19:43Z","timestamp":1328325583000},"page":"225-231","source":"Crossref","is-referenced-by-count":14,"title":["Lipid-altering efficacy and safety profile of co-administered extended release niacin\/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia"],"prefix":"10.1016","volume":"167","author":[{"given":"Fabian","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darbie","family":"Maccubbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waheeda","family":"Sirah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erluo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine McCrary","family":"Sisk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peder","family":"Blomqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"McKenney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2011.12.103_bb0005","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1749-6632.1994.tb17337.x","article-title":"Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS trial. Familial atherosclerosis treatment study","volume":"748","author":"Brown","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0015","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0020","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0025","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jama.1972.03200070084015","article-title":"The coronary drug project research group. The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine","volume":"220","year":"1972","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0030","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","author":"The coronary drug project research group","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0035","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0040","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1021\/jm0603668","article-title":"Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocy clopenta[b]indol-3-yl]-acetic acid (MK-0524)","volume":"50","author":"Sturino","year":"2007","journal-title":"J Med Chem"},{"issue":"108","key":"10.1016\/j.ijcard.2011.12.103_bb0045","article-title":"Lipid-altering efficacy and tolerability profile of extended release niacin\/laropiprant in patients with primary hypercholesterolemia or mixed hyperlipidemia","volume":"28","author":"Maccubbin","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0055","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia","volume":"101","author":"Paolini","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0060","first-page":"90","article-title":"Efficacy and safety profile of co-administered ER niacin\/laropiprant and simvastatin in dyslipidaemia","volume":"16","author":"Gleim","year":"2009","journal-title":"Br J Cardiol"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0070","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1517\/14656566.5.6.1385","article-title":"Extended-release niacin for modifying the lipoprotein profile","volume":"5","author":"Guyton","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0075","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","article-title":"Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies","volume":"102","author":"Danesh","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0080","doi-asserted-by":"crossref","first-page":"22C","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0002-9343(92)90018-7","article-title":"Hepatic toxicity of unmodified and time-release preparations of niacin","volume":"92","author":"Rader","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0090","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0002-9149(97)01016-3","article-title":"Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase","volume":"81","author":"Tato","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0095","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial","volume":"284","author":"Elam","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.12.103_bb0100","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527311022996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527311022996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T06:17:43Z","timestamp":1561270663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527311022996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0167527311022996"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2011.12.103","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}